http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jae-Min Kim(Jae-Min Kim),Hee-Ju Kang(Hee-Ju Kang),Ju-Wan Kim(Ju-Wan Kim),Wonsuk Choi(Wonsuk Choi),Sung-Wan Kim(Sung-Wan Kim),Jung-Chul Kim(Jung-Chul Kim),Byung Jo Chun(Byung Jo Chun),Youngkeun Ahn(You 대한정신약물학회 2023 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.21 No.2
Objective: We investigated effects of serum serotonin and interleukin 18 levels on suicidal ideation (SI) at acute and chronic phases of acute coronary syndrome (ACS). Methods: Recent-onset 969 ACS patients were evaluated for serum serotonin and interleukin 18 levels; and SI by the “suicidal thoughts” item of the Montgomery–Åsberg Depression Rating Scale. After 1-year, 711 patients were re-evaluated for SI. Logistic regression models were used adjustment for potential covariates. Results: Associations between serum interleukin 18 and SI at both phases were significant only in the lower serotonin group. Conclusion: By evaluating serum serotonin and interleukin 18 levels, the clinical prediction of SI of ACS may be improved.
Kim, Ju Han,Chae, Shung-Chull,Oh, Dong Joo,Kim, Hyo-Soo,Kim, Young Jo,Ahn, Youngkeun,Cho, Myeong Chan,Kim, Chong Jin,Yoon, Jung-Han,Park, Hyun-Young UNKNOWN 2016 CIRCULATION JOURNAL Vol.80 No.6
<P>Background: The Korea Acute Myocardial Infarction Registry (KAMIR)-National Institutes of Health (NIH) registry has the aim of evaluating the clinical characteristics, management, and long-term outcomes of patients with acute myocardial infarction (AMI) in Korea. Methods and Results; Patients hospitalized for AMI in 20 tertiary university hospitals in Korea have been enrolled since November 2011. The study is expected to complete the scheduled enrollment of approximately 13,000 patients in October 2015, and follow-up duration is up to 5 years for each patient. As of October 2015, an interim analysis of 13,623 subjects was performed to understand the baseline clinical profiles of the study population. The mean age was 64.1 years; 73.5% were male; and 48.2% were diagnosed with ST-segment elevation AMI. Hypertension is a leading cause of AMI in Korea (51.2%), followed by smoking (38.5%) and diabetes mellitus (28.6%). Percutaneous coronary intervention was performed in 87.4% and its success rate was very high (99.4%). In-hospital, 1-year, and 2-year mortality rates were 3.9%, 4.3%, and 8.6%, respectively. The rates of major adverse cardiac events at 1 and 2 years were 9.6% and 18.8%, respectively. Conclusions: This analysis demonstrated the clinical characteristics of Korean AMI patients in comparison with those of other countries. It is necessary to develop guidelines for Asian populations to further improve their prognosis.</P>
Kim, Jae-Min,Stewart, Robert,Lee, Yong-Seong,Lee, Hee-Joon,Kim, Min Chul,Kim, Ju-Wan,Kang, Hee-Ju,Bae, Kyung-Yeol,Kim, Sung-Wan,Shin, Il-Seon,Hong, Young Joon,Kim, Ju Han,Ahn, Youngkeun,Jeong, Myung H American Medical Association 2018 JAMA Vol.320 No.4
<P>CONCLUSIONS AND RELEVANCE Among patients with depression following recent acute coronary syndrome, 24-week treatment with escitalopram compared with placebo resulted in a lower risk of major adverse cardiac events after a median of 8.1 years. Further research is needed to assess the generalizability of these findings.</P>
Kim, Jae-Min,Bae, Kyung-Yeol,Stewart, Robert,Jung, Bo-Ok,Kang, Hee-Ju,Kim, Sung-Wan,Shin, Il-Seon,Hong, Young Joon,Kim, Ju Han,Shin, Hee-Young,Kang, Gaeun,Ahn, Youngkeun,Kim, Jong-Keun,Jeong, Myung Ho Physicians Postgraduate Press, Inc. 2015 The Journal of clinical psychiatry Vol.76 No.1
<P>Depression is common after acute coronary syndrome (ACS) and has adverse effects on prognosis. There are few evidence-based interventions for treating depression in ACS. This study investigated the efficacy and safety of escitalopram in treating depressive disorders identified 2-14 weeks after a confirmed ACS episode.</P>
Ahn, Youngkeun,Kim, Yongcheol,Chang, Kiyuk,Kim, Weon,Rhee, Moo-Yong,Cha, Kwang Soo,Hyon, Min Su,Shim, Chi Young,Lee, Sung Yun,Kim, Doo Il,Kim, Sang Wook,Lim, Sang-Wook,Han, Kyoo-Rok,Jo, Sang-Ho,Lee, N Williams & Wilkins Co 2018 Medicine Vol.97 No.37
<P><B>Abstract</B></P><P><B>Background:</B></P><P>To determine whether the effectiveness and safety of fixed-dose combinations (FDCs) of amlodipine orotate/valsartan (AML/VAL) 5/160 mg are noninferior to those of valsartan/hydrochlorothiazide (VAL/HCTZ) 160/12.5 mg in hypertensive patients with inadequate response to valsartan 160 mg monotherapy.</P><P><B>Methods:</B></P><P>This 8-week, active-controlled, parallel-group, fixed-dose, multicenter, double-blind randomized controlled, and noninferiority trial was conducted at 17 cardiovascular centers in the Republic of Korea. Eligible patients had mean sitting diastolic blood pressure (msDBP) ≥90 mm Hg despite monotherapy with valsartan 160 mg for 4 weeks. Patients were randomly assigned to treatment with AML/VAL 5/160 mg FDC (AML/VAL) group or VAL/HCTZ 160/12.5 mg FDC (VAL/HCTZ) group once daily for 8 weeks. A total of 238 patients were enrolled (AML/VAL group, n = 121; VAL/HCTZ group, n = 117), of whom 228 completed the study.</P><P><B>Results:</B></P><P>At 8 weeks after randomization, msDBP was significantly decreased in both groups (−9.44 ± 0.69 mm Hg in the AML/VAL group and −7.47 ± 0.71 mm Hg in the VAL/HCTZ group, both <I>P</I> < .001 vs baseline). Between group difference was −1.96 ± 1.00 mm Hg, indicating that AML/VAL 5/160 mg FDC was not inferior to VAL/HCTZ 160/12.5 mg FDC at primary efficacy endpoint. Control rate of BP defined as the percentage of patients achieving mean sitting SBP (msSBP) <140 mm Hg or msDBP <90 mm Hg (target BP) from baseline to week 8 was significantly higher in the AML/VAL group than that in the VAL/HCTZ group (84.3% [n = 102] in the AML/VAL group vs 71.3% [n = 82] in the VAL/HCTZ group, <I>P</I> = .016). At 8 weeks after randomization, mean uric acid level was significantly increased in the VAL/HCTZ group compared to that at baseline (0.64 ± 0.08 mg/dL; <I>P</I> < .001). However, it was slightly decreased from baseline in the AML/VAL group (−0.12 ± 0.08 mg/dL; <I>P</I> = .085). The intergroup difference was significant (<I>P</I> < .001).</P><P><B>Conclusion:</B></P><P>The effectiveness and safety AML/VAL 5/160 mg FDC are noninferior to those of VAL/HCTZ 160/12.5 mg FDC in patients with hypertension inadequately controlled by valsartan 160 mg monotherapy.</P>
대학생의 내현적 자기애와 관계적 공격성의 관계: 정서표현양가성과 정서조절곤란의 이중매개효과
김서현(Kim, Seo-Hyun), 김규태(Kim, Gyu-Tae), 김영근(Kim, Youngkeun) 한국교육치료학회 2024 교육치료연구 Vol.16 No.2
본 연구는 대학생의 내현적 자기애와 관계적 공격성의 관계에서 정서표현양가성과 정서조절곤란의 이중매개효과를 검증하고자 하였다. 이를 위해 온라인 설문을 통한 대학생 총 435명 중 63명을 제외한 372명의 자료를 기반으로 분석하였다. 수집된 자료를 토대로 주요 변인들과의 연관성을 확인하기 위하여 상관분석을 실시하였고, 정서표현양가성과 정서조절곤란이 내현적 자기애와 관계적 공격성 사이에 매개하는지 살펴보기 위해 매개효과를 검증하였다. 주요 결과로는 첫째, 정서표현양가성은 내현적 자기애, 관계적 공격성의 사이에서 부분 매개하는 것으로 나타났으며 관계적 공격성에 유의한 부적 영향을 미치는 것으로 나타났다. 둘째, 정서조절곤란은 내현적 자기애, 관계적 공격성의 사이에서 부분 매개하는 것으로 나타났다. 셋째, 매개변인을 고려했을 때 내현적 자기애가 관계적 공격성에 미치는 영향력은 감소했으나 통계적으로 유의한 것으로 나타나 완전 이중매개 모형이 지지 되었다. 본 연구는 내현적 자기애가 관계적 공격성으로 이어지는 경로에서 정서표현양가성과 정서조절곤란의 역할을 알아보았다는 점에서 이러한 특성을 지닌 대학생의 상담적 개입에 중요한 자료를 제공할 것이라 기대할 수 있다. 마지막으로 연구의 의의와 한계점을 제시하고 후속연구를 위한 제언을 하였다. This study attempted to verify the dual mediating effect of ambivalence and emotional regulation disorder on emotional expression between covert narcissism and relational aggression in college students. To this end, the data of 372 participants collected through the online questionnaire were analyzed. As the main result, first, it was found that ambivalence in emotional expression partially mediated between covert narcissism and relational aggression. Second, it was found that emotional regulation disorder partially mediated between covert narcissism and relational aggression. Third, in the case of considering the mediating variable, the influence on covert narcissism and relational aggression decreased. Still, it was statistically significant, supporting the complete double mediating model. The significance and limitations of this study were discussed, and suggestions for further research were stated.
JaeMin Kim,KyungYeol Bae,HeeJu Kang,SungWan Kim,IlSeon Shin,YoungJoon Hong,JuHan Kim,HeeYoung Shin,YoungKeun Ahn,JongKeun Kim,MyungHo Jeong,JinSang Yoon 대한신경정신의학회 2014 PSYCHIATRY INVESTIGATION Vol.11 No.1
Depression is common after acute coronary syndrome (ACS), adversely affecting cardiac course and prognosis. There have been only a few evidence-based treatment options for depression in ACS. Accordingly, we planned the Korean Depression in ACS (K-DEPACS) study, which investigated depressive disorders in patients with ACS using a naturalistic prospective design, and the Escitalopram for DEPACS (EsDEPACS) trial, which assessed the efficacy and safety of escitalopram for treating major or minor depression in patients with ACS. Participants in the K-DEPACS study were consecutively recruited from patients with ACS who were recently hospitalized at Chonnam National University Hospital, Gwangju, South Korea. Diagnoses were confirmed by coronary angiography from 2005. Data on depressive and cardiovascular characteristics were obtained at 2 weeks, 3 months, 12 months, and every 6 months thereafter following the index ACS admission. The K-DEPACS participants who met the DSM-IV criteria for major or minor depressive disorder were randomly assigned to groups in the 24-week, double-blind, placebo-controlled EsDEPACS trial beginning in 2007. The outcome of treatments for depressive and other psychiatric symptoms, issues related to safety, including general adversity, and cardiovascular factors were assessed. The K-DEPACS study can significantly contribute to research on the complex relationships between depression and ACS. The results of the EsDEPACS trial provide an additional treatment option for clinicians treating these patients.
Hyun Kuk Kim,Youngkeun Ahn,Kiyuk Chang,Young-Hoon Jeong,Joo-Yong Hahn,Eun Ho Choo,김민철,Hyo-Soo Kim,Weon Kim,Myeong Chan Cho,Yangsoo Jang,Chong Jin Kim,Myung Ho Jeong,Shung Chull Chae 대한심장학회 2020 Korean Circulation Journal Vol.50 No.10
Clinical practice guidelines published by the European Society of Cardiology and the American College of Cardiology/American Heart Association summarize the available evidence and provide recommendations for health professionals to enable appropriate clinical decisions and improve clinical outcomes for patients with acute myocardial infarction (AMI). However, most current guidelines are based on studies in non-Asian populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute Myocardial Infarction Registry is the first nationwide registry to document many aspects of AMI from baseline characteristics to treatment strategies. There are well-organized ongoing and published randomized control trials especially for antiplatelet therapy among Korean patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial Infarction review recent published studies during the current PCI era, and have summarized the expert consensus for the pharmacotherapy of AMI.
( Uh Jin KIM ),( Seunghun LEE ),( Myung Ho JEONG ),( Ju Han KIM ),( HyukJin PARK ),( Ji Eun KIM ),( Youngkeun AHN ),( Jong Hyun KIM ),( Shung Chull CHAE ),( Young Jo KIM ),( Seung Ho HUR ),( In Whan S 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: The correlation between obesity and metabolic syndrome (MetS) remains unclear. This study aims to investigate impact of obesity phenotype on clinical outcomes with ST-segment elevation myocardial infarction (STEMI). Methods: We analyzed in-hospital mortality and major adverse cardiac events (MACE) of 2,606 obese patients who underwent primary percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry from November 2005 to October 2010. Patients were divided into two groups: unhealthy (any of the Mets components) obesity (BMI =25 kg/m2) and healthy (none of the Mets components) obesity. Results: The unhealthy obesity group was composed of 703 patients (27%) and healthy obesity group 1,903 patients (73%). Unhealthy obesity was more frequent in female (25.9% vs. 10.1%, P<0.001) and multi-vessel disease (53.1% vs. 47.6%, P=0.012). There were no signifi cant differences in other baseline characteristics, angiographic and procedural fi ndings, and prescribed medications between two groups. The overall incidence of complications after PCI (13.1% vs. 10.7%, P=0.097) and in-hospital mortality (1.9% vs. 1.6%, P=0.521) were similar in unhealthy obesity group compared with healthy obesity group. By the multivariate Cox regression analyses, the presence of Mets in obese patients was not an independent factor for predicting the adjusted MACE rate at one-month (HR 1.19, 95% CI 0.56-2.54, P=0.645), six-month (HR 1.48, 95% CI 0.94-2.32, P=0.088), and twelve-month (HR 1.10, 95% CI 0.75-1.61, P=0.622). Conclusions: Obesity phenotype is not an independent prognostic factor for patients with STEMI who undergoing primary PCI. The risk stratifi cation by presence or absence of Mets is not useful in these patients.